昆士兰州复发性骨髓瘤患者赴上海接受双靶点CAR-T治疗
- When
- 2025
- City
- Shanghai
- 自报总费用
- Not reported
- Shared on
- Patient organisation story
- Patient from
- Australia
自述最后核验
时间线
2018
Diagnosed with aggressive myeloma; tandem and later a third stem cell transplant.
2025
Relapses; not eligible for Australian CAR-T trials. Contacts a New Zealand patient found on Facebook, then emails a Shanghai professor who replies the same day.
2025
Three weeks later flies to China; T cells sent to Beijing for manufacturing; BCMA and GPRC5D CAR-T infused.
2025
Two weeks in hospital after infusion, mild CRS, readmitted for a viral respiratory infection; seven weeks in China total.
顺利之处
- 离华时骨髓检查未见骨髓瘤细胞（其自述报告）
- 与澳大利亚和英国相比，医疗护理质量良好
困难之处
- 动用退休储蓄支付费用
- 护士不提供日常个人护理，需要有陪护人员
- 曾因感染再次住院
Individual experience; outcomes vary. This story is a summary linking to its source; follow the link for the original account.
来源
本站仅提供信息，不构成医疗建议、诊断或治疗推荐。请咨询你的医生。紧急情况请立即拨打当地急救电话。